The development of new effective antibiotics is proceeding according to the world health organization (WHO) threat slowly.
Declining investment and lack of real innovations were the efforts to combat multidrug-resistant infections that undermine, said the WHO, citing two new reports.
Therefore, currently 60 antimicrobial agents – 50 antibiotics and 10 Biopharmaceuticals are tested in humans. This would bring compared to existing treatments, but little additional Benefit. In addition, only a few focused on the most important resistant bacteria.
“Never before has the threat of antibiotic resistance, the immediate, and the need for solutions was urgent,” said WHO chief Tedros Adhanom Ghebreyesus.
Development of new antibiotics is stalling
It should also be noted that the research and development for antibiotics in the first line will be driven forward by small or medium-sized enterprises, while large corporations have left the field, the WHO.
The view on the Situation with drugs, which are still in an earlier stage of development, voice a little more optimistic.
There, 252 funds, aimed at the biggest of the WHO-defined problem areas.
First drugs of this Generation, but would probably at the earliest in ten years on the market.
Resistance can develop when a use of Antibiotics, some bacteria survive. These resistant bacteria can multiply. Of particular concern is the spread of bacteria such as Acinetobacter, Escherichia coli and Klebsiella pneumoniae, circulate often in hospitals according to the WHO.
They may cause pneumonia, blood poisoning, and wound infections.
Deutsche Presse-Agentur (dpa)
*The post “the fight against resistant bacteria: New antibiotics according to the WHO, too little” is published by FitForFun. Contact with the executives here.